RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > FDA Fights Cancer Drug Shortages

FDA Fights Cancer Drug Shortages

Posted 22 February 2012 | By

The US Food and Drug Administration (FDA) is taking steps to increase the supply of two important cancer drugs: methotrexate and doxil.

CNN's The Chart blog reported that Doxil will be replaced by Lipodox, a drug that is currently manufactured overseas and has not been approved by FDA. It has been evaluated to ensure that it does not pose any risks to patients.

FDA is boosting the supply of methotrexate with the approval of a new manufacturer and the release of addition supplies from a pharmaceutical delivery company.

The Chart reported FDA claims it has prevented 114 drug shortages since President Obama's executive order directing such action.

Read more:
CNN: FDA Continues to Fight Drug Shortages in US


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.